Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia

Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) in adults, data on safety and efficacy in pediatric patients are scarce. We report the use of InO in 51 children with relapsed/refractory ALL treated in the compassionate use progr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Leukemia
Huvudupphovsmän: Bhojwani, Deepa, Sposto, Richard, Shah, Nirali N., Rodriguez, Vilmarie, Yuan, Constance, Stetler-Stevenson, Maryalice, O’Brien, Maureen M., McNeer, Jennifer L., Quereshi, Amrana, Cabannes, Aurelie, Schlegel, Paul, Rossig, Claudia, Dalla-Pozza, Luciano, August, Keith, Alexander, Sarah, Bourquin, Jean-Pierre, Zwaan, Michel, Raetz, Elizabeth A., Loh, Mignon L., Rheingold, Susan R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2018
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6438769/
https://ncbi.nlm.nih.gov/pubmed/30267011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-018-0265-z
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk